✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
News · 12 dated items

GLP-1 Telehealth News: What Changed Through November 20, 2026

Released: Last reviewed:

FDA, CMS and pricing developments, newest first, each with its primary source and what it means if you pay cash.

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Lilly ObesityWeek data: tirzepatide in adolescents, EloraTZP and retatrutide

Lilly’s November 14 release says Zepbound reduced BMI by an average 21.4% at 72 weeks in adolescents (SURMOUNT-ADOLESCENTS) and lists phase 2 EloraTZP and retatrutide results. These are conference data, not all peer-reviewed.

What it means for cash-pay patients: Nothing new to buy: Zepbound is still approved only for adults, and EloraTZP and retatrutide are not approved.

Source: Eli Lilly release · official, company data · verified November 20, 2026

REDEFINE 9: lower-dose CagriSema about 21% weight loss at 68 weeks

The Lancet Diabetes & Endocrinology published REDEFINE 9: cagrilintide-semaglutide 1.0/1.0 mg and 1.7/1.7 mg produced about 21% mean weight loss versus 2.0% with placebo (efficacy estimand). Novo plans a U.S. launch in early 2027, subject to approval.

What it means for cash-pay patients: CagriSema is not FDA-approved, and FDA says cagrilintide cannot be used in compounding, so any product sold now as CagriSema is unapproved.

Source: PubMed 43033821 · official, peer-reviewed · verified November 20, 2026

FDA requires a NAION eye warning on all approved GLP-1 labels

FDA’s Drug Safety Communication requires every GLP-1 receptor agonist label to add a potential increased risk of NAION, a sudden, painless loss of vision in one eye. In FDA’s analysis of 126 trials the rate was 6.4 versus 3.8 cases per 100,000 person-years. Compounded products are not mentioned.

What it means for cash-pay patients: Anyone taking semaglutide or tirzepatide should report sudden vision loss to a clinician right away.

Source: FDA Drug Safety Communication · official, effective · verified November 20, 2026

Hims & Hers 10-Q: FTC case hearing set for January 14, 2027

Hims’ third-quarter filing says it moved to dismiss the July 29, 2026 FTC, Utah and Los Angeles County complaint, with a hearing currently set for January 14, 2027, and accrued about $60 million for the matter. It says compounded GLP-1s are now offered “on a limited scale.”

What it means for cash-pay patients: The case concerns subscription, cancellation and privacy practices and is unresolved; read Hims’ cancellation terms before subscribing.

Source: SEC Form 10-Q · official · verified November 20, 2026

Lilly and Hims & Hers: Zepbound and Foundayo at Lilly’s self-pay prices

Lilly and Hims said eligible Hims patients can buy Zepbound and Foundayo at Lilly’s self-pay prices, starting at $299 and $149 a month, without leaving the Hims platform. The release states no Hims membership fee.

What it means for cash-pay patients: Compare Lilly’s price plus any platform fee against all-in compounded prices before choosing a route.

Source: Lilly and Hims release · official, effective · verified November 20, 2026

LifeMD’s pharmacy to dispense Lilly self-pay Zepbound and Foundayo (reported)

LifeMD said its affiliated mail-order pharmacy can dispense Zepbound and Foundayo at Lilly’s self-pay prices to patients of LifeMD-affiliated providers. The release gives no prices and was read through a syndicated copy.

What it means for cash-pay patients: LifeMD’s own $149 monthly program fee still applies on top of the drug price.

Source: LifeMD release (syndicated) · reported · verified November 20, 2026

NAD tells Good Life Meds to drop “personalized” claims for compounded tirzepatide

In a challenge brought by Lilly, the National Advertising Division recommended that Good Life Meds stop health-benefit and “personalized” claims for its compounded “Tirzepatide+” products. Good Life said it disagrees but will comply.

What it means for cash-pay patients: NAD is industry self-regulation, not FDA or a court; ask any program what is in the vial and what evidence supports added ingredients.

Source: BBB National Programs decision · official, self-regulatory · verified November 20, 2026

FDA warning letter to RonanRx over “FDA-approved compounded” and “American made” claims

FDA’s October 30 letter, posted November 3, says RonanRx made false or misleading claims about compounded semaglutide and tirzepatide, and that FDA’s records list no U.S.-registered maker of their active ingredients for compounding. It is the only telehealth letter posted in the October 13 to November 17 window.

What it means for cash-pay patients: Treat “FDA-approved compounded” or “made in America” claims as red flags. Our warning-letter analysis covers all 56 telehealth letters issued in 2026.

Source: FDA warning letter 737905 · official · verified November 20, 2026

Medicare’s $274 negotiated price for Ozempic, Rybelsus and Wegovy starts January 1, 2027

CMS updated its negotiated-price file on November 2, 2026. Its fact sheet, first published in 2025, lists a maximum fair price of $274 for a 30-day supply of Ozempic, Rybelsus and Wegovy, effective January 1, 2027. It applies inside Medicare Part D and is separate from the $50 Medicare GLP-1 Bridge copay.

What it means for cash-pay patients: Medicare only: cash prices at NovoCare, pharmacies and telehealth programs do not change.

Source: CMS fact sheet · official, effective 2027-01-01 · verified November 20, 2026

HHS draft policy on compounding six peptides, including BPC-157

A Federal Register notice (91 FR 68526) announced a draft HHS policy under which it would not take enforcement action against 503A compounding with peptides in its Appendix A. Law-firm summaries list BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500; HHS’s own PDF could not be read.

What it means for cash-pay patients: No GLP-1 is covered; the peptides remain unapproved and the policy is a draft.

Source: Federal Register · official notice; peptide list reported · verified November 20, 2026

Class II recall of compounded semaglutide and tirzepatide combination vials (Victory Medical Center Pharmacy)

FDA’s November 11 enforcement report lists a voluntary recall of semaglutide/L-carnitine and tirzepatide combination vials distributed in Colorado, Florida and Texas for “lack of processing controls.” It follows October recalls from Carolina Infusion, Apothecary Pharma and Houston Rx.

What it means for cash-pay patients: Check the pharmacy name and lot on your vial label; none of these pharmacies is named on the plan pages of the programs we score.

Source: FDA enforcement reports (openFDA) · official · verified November 20, 2026

Lilly third quarter: U.S. Zepbound revenue up 48% while realized prices fell

Lilly reported U.S. Zepbound revenue of $5.3 billion, up 48%, with U.S. realized prices down 7%, mainly because of Zepbound. The release does not mention LillyDirect prices.

What it means for cash-pay patients: No change to Lilly’s cash prices; realized price is a net figure after rebates.

Source: SEC Form 8-K exhibit · official · verified November 20, 2026

KFF: 18% of large employers cover GLP-1s for weight loss

KFF’s 2026 Employer Health Benefits Survey finds 18% of firms with 200 or more workers cover GLP-1s primarily for weight loss, similar to 19% last year; 12% of non-covering large firms stopped covering them in the past year.

What it means for cash-pay patients: Most workers at large employers still pay cash for weight-loss GLP-1s.

Source: KFF survey report · official · verified November 20, 2026

No material verified change (checked November 20, 2026)

  • The 503B bulks-list exclusion for tirzepatide, semaglutide and liraglutide is still a proposal; the Federal Register showed no final notice.
  • Medicare GLP-1 Bridge and BALANCE pages: unchanged since October.
  • State telehealth and compounding rules: no change verified on an official state site in the window.
  • New compounded telehealth entrants or price announcements: none verified.
  • NexLife’s prices: unchanged since November 6, 2026.

Lilly sets October 29 for third-quarter results; Medicare open enrollment begins

Lilly said it will report third-quarter 2026 results on October 29. Medicare open enrollment runs October 15 to December 7, with changes effective January 1.

What it means for cash-pay patients: Watch the Lilly call for Zepbound and Foundayo self-pay trends and any 2027 LillyDirect pricing.

Source: investingnews.com · confirmed

CNN reports GLP-1s reaching people with eating disorders through telehealth

CNN reported clinicians seeing more patients with anorexia using GLP-1s, some obtained online after little screening. One patient said he misstated his weight to a telehealth company; Hims & Hers told CNN eating-disorder screening is mandatory in its process.

What it means for cash-pay patients: Expect closer scrutiny of questionnaire-only intake. A careful program asks about eating-disorder history and checks weight and BMI.

Source: edition.cnn.com · confirmed (press report)

Walmart adds Ozempic and Mounjaro for type 2 diabetes in 2027, not for weight loss

CNBC reported that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after prior authorization. GLP-1s for weight loss remain excluded.

What it means for cash-pay patients: Employees who want a GLP-1 for weight loss stay on cash pay.

Source: www.cnbc.com · confirmed (press report)

Mochi Health’s per-dose compounded pricing gets press attention

Mochi’s own blog post, first published in August and updated September 18, lists compounded semaglutide at $60–$99 a month and tirzepatide at $90–$199 by dose, with membership billed separately. A press article on October 13 covered it alongside a new lab-testing service.

What it means for cash-pay patients: Entry doses got cheaper at Mochi; higher doses cost what they did before, plus membership.

Source: Mochi Health blog post (source) · confirmed

Ozari Health announces two compounded GLP-1 plans

A paid press release described Ozari One (semaglutide $86 and tirzepatide $125 a month, billed quarterly, not in California) and Ozari Select (choice of additive, $99–$235 by billing term), both at the same price for every dose and filled by five named 503A pharmacies.

What it means for cash-pay patients: Not yet in our index: we have not read Ozari’s own pricing pages.

Source: finance.yahoo.com · reported (company release)

FDA posts warning letters to two “generic semaglutide” websites

FDA posted letters 737806 (onlinegenericmedicine.com, “Semanat”) and 737810 (cheapmedicineshop.com, “Semanext”), dated September 23 and 24, saying the injectable semaglutide they sold is unapproved and misbranded.

What it means for cash-pay patients: Online “generic semaglutide” is not an FDA-approved product. Our full report.

Source: www.fda.gov · confirmed

FDA updates its page on unapproved GLP-1 drugs

FDA’s consumer page, current as of October 1, lists telehealth red flags, says compounded multi-dose vials should be discarded 28 days after first use, warns against salt forms and states that retatrutide and cagrilintide cannot be used in compounding under federal law.

What it means for cash-pay patients: Use it as a checklist when a price looks too good to be true.

Source: www.fda.gov · confirmed

Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss

Under the state’s FY2027 budget, Rhode Island Medicaid ended coverage of Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss, effective October 1. Coverage continues for diabetes and other approved uses.

What it means for cash-pay patients: Affected members must self-pay or stop treatment.

Source: www.point32health.org · confirmed

Medicare GLP-1 Bridge runs through 2027; BALANCE model will not start in Medicare in 2027

CMS pages say the $50-copay Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027, outside the Part D benefit, and that the BALANCE model will not launch in Medicare in 2027.

What it means for cash-pay patients: Eligible Medicare patients have a low-cost brand option through 2027.

Source: www.cms.gov · confirmed

Two men charged over counterfeit Ozempic distribution

FDA announced charges in the Middle District of Florida against two Indian nationals accused of distributing counterfeit Ozempic between 2023 and 2024. An indictment is an allegation, not a conviction.

What it means for cash-pay patients: Buy brand GLP-1s only through licensed pharmacies or the manufacturers’ programs.

Source: www.fda.gov · confirmed

Novo Nordisk: most Wegovy pill prescriptions are self-pay

At its Capital Markets Day, Novo said the Wegovy pill had passed 7 million prescriptions in 2026, with about 90% self-pay, and described partnerships with nine or more telehealth companies.

What it means for cash-pay patients: Cash pay is now the main route to the Wegovy pill.

Source: www.novonordisk.com · confirmed

FDA warning letter to Empower Pharmacy over compounded GLP-1 combinations

Letter 738238, posted September 22, says Empower’s compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin “appear to be essentially copies” of approved drugs and cites insanitary conditions.

What it means for cash-pay patients: Ask any program which pharmacy fills your prescription. Empower profile.

Source: www.fda.gov · confirmed

Earlier milestones

FDA declares the semaglutide shortage resolved

FDA removed semaglutide injection from its drug shortage list, which ended the shortage-based basis for widespread compounding of copies.

Source: U.S. FDA (fda.gov) · confirmed

FDA declares the tirzepatide shortage resolved

FDA confirmed the tirzepatide shortage was resolved after reviewing Lilly’s supply data.

Source: U.S. FDA (fda.gov) · confirmed

Wegovy approved to reduce cardiovascular risk

FDA approved Wegovy to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial.

Source: U.S. FDA (fda.gov) · confirmed

Wegovy approved for chronic weight management

FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in adults with obesity or overweight with a weight-related condition.

Source: U.S. FDA (fda.gov) · confirmed

Items marked “press report” or “company release” are not primary sources. Corrections: americantelehealthreview@gmail.com.